Evidence map›Paper›PMID 40645925›Full record

ArticleNature communications2025

Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys.

Jared Pitts, J Lizbeth Reyes Zamora, Savrina Manhas, Thomas Aeschbacher, Josolyn Chan, Vincent Cutillas, Varsha Nair, Nicholas C Riola, Arya Vijjapurapu, Meghan S Vermillion and 29 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Jared Pitts *Gilead Sciences, Inc., Foster City, CA, USA.
J Lizbeth Reyes Zamora *Gilead Sciences, Inc., Foster City, CA, USA.ORCID http://orcid.org/0000-0003-3000-817X
Savrina ManhasGilead Sciences, Inc., Foster City, CA, USA.
Thomas AeschbacherGilead Sciences, Inc., Foster City, CA, USA.
Josolyn ChanGilead Sciences, Inc., Foster City, CA, USA.
Vincent CutillasGilead Sciences, Inc., Foster City, CA, USA.
Varsha NairGilead Sciences, Inc., Foster City, CA, USA.ORCID http://orcid.org/0009-0000-8121-9052
Nicholas C RiolaGilead Sciences, Inc., Foster City, CA, USA.ORCID http://orcid.org/0009-0000-5445-0515
Arya VijjapurapuGilead Sciences, Inc., Foster City, CA, USA.ORCID http://orcid.org/0009-0000-1426-7919
Meghan S VermillionLovelace Biomedical Research Institute, Albuquerque, NM, USA.
Stacey EngGilead Sciences, Inc., Foster City, CA, USA.ORCID http://orcid.org/0009-0003-8605-3807
Christopher RichardsGilead Sciences, Inc., Foster City, CA, USA.ORCID http://orcid.org/0000-0003-0832-8951
Dong HanGilead Sciences, Inc., Foster City, CA, USA.
Jason K PerryGilead Sciences, Inc., Foster City, CA, USA.
Subhra ChaudhuriGilead Sciences, Inc., Foster City, CA, USA.
Szu-Wen LiuGilead Sciences, Inc., Foster City, CA, USA.
Clarissa MartinezGilead Sciences, Inc., Foster City, CA, USA.
Nadine PeinovichGilead Sciences, Inc., Foster City, CA, USA.
Kai-Hui SunGilead Sciences, Inc., Foster City, CA, USA.ORCID http://orcid.org/0009-0008-8206-7933
Arthur CaiGilead Sciences, Inc., Foster City, CA, USA.
Ross MartinGilead Sciences, Inc., Foster City, CA, USA.ORCID http://orcid.org/0000-0003-2105-4748
Jasmine MoshiriGilead Sciences, Inc., Foster City, CA, USA.
Charlotte HedskogGilead Sciences, Inc., Foster City, CA, USA.
Darius BabusisGilead Sciences, Inc., Foster City, CA, USA.ORCID http://orcid.org/0000-0001-5599-1671
Dustin S SiegelGilead Sciences, Inc., Foster City, CA, USA.ORCID http://orcid.org/0009-0008-1365-0287
Rao KallaGilead Sciences, Inc., Foster City, CA, USA.
Vasanthi AvadhanulaMolecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Pedro A PiedraMolecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5839-0879
Kim StobbelaarLaboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Antwerp, BE, Belgium.
Peter L DelputteLaboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Antwerp, BE, Belgium.ORCID http://orcid.org/0000-0003-3972-616X
Caleb MarceauGilead Sciences, Inc., Foster City, CA, USA.
Roberto MateoGilead Sciences, Inc., Foster City, CA, USA.
Evguenia MaiorovaGilead Sciences, Inc., Foster City, CA, USA.
Hongmei MoGilead Sciences, Inc., Foster City, CA, USA.
Raju SubramanianGilead Sciences, Inc., Foster City, CA, USA.
Richard L MackmanGilead Sciences, Inc., Foster City, CA, USA.
Tomas CihlarGilead Sciences, Inc., Foster City, CA, USA.
Simon P FletcherGilead Sciences, Inc., Foster City, CA, USA.
John P BilelloGilead Sciences, Inc., Foster City, CA, USA. john.bilello@gilead.com.ORCID http://orcid.org/0000-0003-4327-1727

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) is a significant cause of morbidity and mortality in high-risk populations. Although prophylactic options are available, there are no effective oral therapeutics for RSV infection. Obeldesivir (ODV) is an orally bioavailable prodrug of the nucleoside analog GS-441524, which is converted intracellularly to its active nucleoside triphosphate and inhibits the RSV RNA polymerase. Here we report the potent antiviral activity of ODV against geographically and temporally diverse RSV A and B clinical isolates (EC

Indexed as

Antiviral AgentsNucleosidesRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsAdenosineAdministration, OralAnimalsChlorocebus aethiopsDisease Models, AnimalDrug Resistance, ViralFemaleHumansAdenosineAntiviral AgentsGS-441524Nucleosides

Identifiers

PMID40645925
PMCPMC12254204

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.